At last, pioglitazone increases circulating adiponectin production which activates hepatic AMPK signaling and down-regulates the mitogen-activated protein kinase pathways (mainly ERK/JNK/cJUN), thus inhibiting HCC development in cirrhotic rodent models [43]. This evidence concerns the gene JUN and hepatocellular carcinoma.